Carving Out New Spaces In Cancer Immunotherapy
An Interview With iTeos Therapeutics co-founder, president and CEO Michel Detheux
Executive Summary
With a combined $335m raised in a crossover series B funding and an IPO last summer, Cambridge, MA-based iTeos Therapeutics has the juice to move its two cancer immunotherapy clinical programs forward.